190 related articles for article (PubMed ID: 34905599)
1. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients.
de Masson A; Darbord D; Dobos G; Boisson M; Roelens M; Ram-Wolff C; Cassius C; Le Buanec H; de la Grange P; Jouenne F; Louveau B; Sadoux A; Bouaziz JD; Marie-Cardine A; Bagot M; Moins-Teisserenc H; Mourah S; Battistella M
Blood; 2022 Mar; 139(12):1820-1832. PubMed ID: 34905599
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M; Kopp E; McCann S; Cantrell W
Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
[TBL] [Abstract][Full Text] [Related]
3. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
[TBL] [Abstract][Full Text] [Related]
4. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
5. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
[TBL] [Abstract][Full Text] [Related]
6. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
Afifi S; Mohamed S; Zhao J; Foss F
Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
[No Abstract] [Full Text] [Related]
7. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
8. Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series.
Trum NA; Zain J; Martinez XU; Parekh V; Afkhami M; Abdulla F; Carson KR; Rosen ST; Bennett CL; Querfeld C
Br J Dermatol; 2022 Jan; 186(1):153-166. PubMed ID: 34427917
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan.
Ishitsuka K; Yasukawa T; Tsuji Y
Hematol Oncol; 2024 Jul; 42(4):e3292. PubMed ID: 38847317
[TBL] [Abstract][Full Text] [Related]
11. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.
Ohuchi K; Fujimura T; Lyu C; Amagai R; Muto Y; Aiba S
Dermatol Ther; 2020 Nov; 33(6):e14099. PubMed ID: 32725764
[TBL] [Abstract][Full Text] [Related]
12. C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.
Geller S; Hollmann TJ; Horwitz SM; Myskowski PL; Pulitzer M
Histopathology; 2020 Jan; 76(2):222-232. PubMed ID: 31355940
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
Mukai M; Maeda H; Narushima K; Mould DR; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
[TBL] [Abstract][Full Text] [Related]
15. Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Morimura S; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Invest Dermatol; 2012 Apr; 132(4):1280-9. PubMed ID: 22297640
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
Fernández-Guarino M; Ortiz P; Gallardo F; Llamas-Velasco M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396877
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.
Ohuchi K; Fujimura T; Kambayashi Y; Amagai R; Lyu C; Tanita K; Sato Y; Aiba S
Dermatol Ther; 2020 Jul; 33(4):e13487. PubMed ID: 32362053
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.
Ollila TA; Sahin I; Olszewski AJ
Onco Targets Ther; 2019; 12():1085-1094. PubMed ID: 30799938
[TBL] [Abstract][Full Text] [Related]
19. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
20. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.
Chang DK; Sui J; Geng S; Muvaffak A; Bai M; Fuhlbrigge RC; Lo A; Yammanuru A; Hubbard L; Sheehan J; Campbell JJ; Zhu Q; Kupper TS; Marasco WA
Mol Cancer Ther; 2012 Nov; 11(11):2451-61. PubMed ID: 22869555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
